Research progress on serum-based assessment methods for liver fibrosis in patients with non-alcoholic fatty liver disease
10.3969/j.issn.1006-5725.2025.15.002
- VernacularTitle:非酒精性脂肪肝患者肝脏纤维化血清学测评方法的研究进展
- Author:
Xueying MA
1
;
Xiangming MA
1
Author Information
1. 华北理工大学附属开滦总医院肝胆外科(河北 唐山 063001)
- Publication Type:Journal Article
- Keywords:
non-alcoholic fatty liver disease;
hepatic fibrosis;
non-invasive examination;
serological markers
- From:
The Journal of Practical Medicine
2025;41(15):2290-2303
- CountryChina
- Language:Chinese
-
Abstract:
Non-alcoholic fatty liver disease(NAFLD)has become a significant global public health concern,posing substantial challenges to healthcare systems worldwide.The condition is characterized by pathological changes such as hepatic steatosis,fibrosis,and cirrhosis,with the extent of liver fibrosis serving as a key determi-nant in assessing disease progression.Due to the limitations of liver biopsy in evaluating fibrosis,there has been a growing emphasis on the clinical application of non-invasive biomarkers.This article provides a comprehensive review of four widely used serological fibrosis scoring systems for assessing NAFLD-related liver fibrosis and offers guidance on model selection tailored to specific patient populations.It further explores disease-specific scoring methodologies for patients with comorbidities,population-specific evaluation strategies,combined scoring systems,and criteria for selecting prognostic models.The discussion aims to provide both theoretical insights and practical recommendations for the future implementation of serological fibrosis assessment in NAFLD management.
